Piper Sandler analyst Jeff Garro initiates coverage on Certara (NASDAQ:CERT) with a Overweight rating and announces Price Target of $28.
Piper Sandler Initiates Coverage On Certara with Overweight Rating, Announces Price Target of $28
Piper Sandler analyst Jeff Garro initiates coverage on Certara (NASDAQ:CERT) with a Overweight rating and announces Price Target of $28.
Related Posts
On Jan 16, Elevai Labs Inc Entered Into A License Agreement With INmune Bio, Inc.; INmune Granted The Co Certain Worldwide Exclusive And Non-Exclusive License Rights To Develop, Manufacture, And Commercialize INmunes’s EMx Technology
- SEC Filing On January 16, 2023, Elevai Labs, Inc., a Delaware corporation (the "Company"), entered into a License Agreement (the "License Agreement") with INmune Bio, Inc., a Nevada corporation ("INmune"). Under
Why Super Micro Computer Stock (SMCI) Is Diving Today
Super Micro Computer Inc (NASDAQ: SMCI) shares are trading lower by 3.5% to $263.80 Friday morning after the company announced pricing of a public offering of common stock.
Needham Maintains Buy on Glaukos, Lowers Price Target to $65
Needham analyst David Saxon maintains Glaukos (NYSE:GKOS) with a Buy and lowers the price target from $66 to $65.